title: Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy.
abstract: OBJECTIVE
  To evaluate the feasibility and morbidity of total laparoscopic class C2 radical hysterectomy (TLRH) with pelvic lymphadenectomy in patients with locally advanced cervical cancer stage IB2 to IIB after neoadjuvant chemotherapy (NACT).
  
  
  METHODS
  A prospective study was conducted from October 2004 to September 2009. Cervical cancer patients, stage IB2-IIB with complete clinical response after 3 courses of NACT with paclitaxel 175 mg/m(2), ifosfamide 5 g/m(2) and cisplatin 75 mg/m(2) (TIP) underwent TLRH.
  
  
  RESULTS
  Forty patients were included, with a median age of 46 years (range, 25-65), BMI of 24 kg/m(2) (range, 15-49). FIGO staging was IB2 in 23, IIA > 4 cm in 6 and IIB in 11 patients. Four patients required conversion to laparotomy. Pathological evaluation showed 9 complete response (pCR), 9 partial response (pPR1) with microscopic tumour, and 15 partial response (pPR2) with macroscopic tumour. Three patients had no response. The median operative time was 305 min (range, 215-430); the median estimated blood loss was 250 ml (range, 100-400), with four postoperative blood transfusion; the median number of removed pelvic lymph nodes was 25 (range, 11-64). The median length of hospital stay was 6 days (range, 3-12). The median follow-up time was 37 months (range, 10-69), with three patients having a recurrence. One patient died of disease (DOD) after 12 months.
  
  
  CONCLUSIONS
  TLRH can be safely performed in patients with stage IB2-IIB carcinoma of cervix after NACT, with advantages of minimal blood loss and morbidity.
authors.affiliation: Division of Gynecologic Oncology, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Vizza
authors.forename: A
authors.initials: A
authors.lastname: Pellegrino
authors.forename: R
authors.initials: R
authors.lastname: Milani
authors.forename: R
authors.initials: R
authors.lastname: Fruscio
authors.forename: E
authors.initials: E
authors.lastname: Baiocco
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
authors.forename: A
authors.initials: A
authors.lastname: Savarese
authors.forename: F
authors.initials: F
authors.lastname: Tomao
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: Corrado
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000473:pathology / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D007558:Italy; D010535:Laparoscopy / Q000009:adverse effects; D007902:Length of Stay; D008197:Lymph Node Excision / Q000009:adverse effects; D008875:Middle Aged; D009017:Morbidity; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D010388:Pelvis; D011446:Prospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery*